RR: Sulfonylurea inadequacy: Efficacy of addition ofinsulin over 6 years in patients with type 2 diabetesin the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330–336. 7. Kerr D, Cavan D: Treating obese patients with poorly controlled diabetes: Confessions of an insulin thera-pist. Diabetes Metab Res Rev 1999;15:219–225. 8. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M,Wang Y, Baron AD: Synthetic exendin-4 (exenatide)significantly reduces postprandial and fasting plasmaglucose in subjects with type 2 diabetes. J Clin En-docrinol Metab 2003;88:3082–3089. 9. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic con-trol of exenatide (synthetic exendin-4) additive to ex-isting metformin and/or sulfonylurea treatment inpatients with type 2 diabetes. Diabetes Care 2003;26:2370–2377. 10. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka